Your browser doesn't support javascript.
loading
Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.
Lv, Lingshuang; Li, Tiecheng; Xu, Kun; Shi, Peiyi; He, Biyu; Kong, Weimin; Wang, Jianming; Sun, Jian.
Afiliação
  • Lv L; Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Li T; Department of Tuberculosis, the Fourth People's Hospital of Lianyungang City, Lianyungang, China.
  • Xu K; Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Shi P; Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China.
  • He B; Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Kong W; Department of Thoracic Surgery, the First People's Hospital of Yancheng City, Yancheng, China.
  • Wang J; Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Sun J; Department of Thoracic Surgery, the First People's Hospital of Yancheng City, Yancheng, China.
Infect Drug Resist ; 11: 147-154, 2018.
Article em En | MEDLINE | ID: mdl-29416359
ABSTRACT

PURPOSE:

Multidrug-resistant tuberculosis (MDR-TB) requires long-term treatment, has a high fatality rate, and constitutes a global threat. Earlier detection of treatment failure is required to predict therapeutic efficacy. PATIENTS AND

METHODS:

We enrolled MDR-TB patients consecutively from January 2011 through December 2012 in Lianyungang, China. Sputum smear microscopy tests and sputum cultures were performed once a month for the first 6 months following initiation of antituberculosis treatment and once every 2 months thereafter until the end of therapy. The sensitivity, specificity and area under the receiver operating characteristic curve (AUC) were used with a 95% CI to estimate the role of sputum bacteriology conversion in predicting treatment outcomes.

RESULTS:

Among the 92 MDR-TB patients enrolled in this study, 40.2% had poor treatment outcomes. The median initial sputum bacteriology conversion time was 1 month. Patients having 2-month sputum smear conversions (adjusted odds ratio [OR] 7.19, 95% CI 2.60-19.84) or culture conversions (adjusted OR 2.88, 95% CI 1.11-7.45) were more likely to experience good outcomes. The sensitivity and specificity obtained when using two-month sputum smear conversions to predict treatment outcomes were 67.6% (95% CI 50.2-82.0) and 76.4% (95% CI 63.0-86.8), respectively. The sensitivity and specificity obtained when using 2-month culture conversions to predict treatment outcomes were 48.6% (95% CI 32.0-65.6) and 74.5% (95% CI 61.0-85.3), respectively. The AUC for two-month smear conversions was 0.72 (95% CI 0.62-0.81), significantly higher than that obtained for 2-month culture conversions (0.62, 95% CI 0.52-0.72) (χ2 = 4.18, P = 0.041).

CONCLUSION:

The prognoses of MDR-TB patients displaying persistent sputum positivity were inferior to those for whom sputum bacteriology conversion was observed. Thus, sputum smear conversion results obtained 2 months after treatment initiation may provide a potential means for predicting MDR-TB treatment outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Infect Drug Resist Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Infect Drug Resist Ano de publicação: 2018 Tipo de documento: Article